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Abstract
Background aims. Growing evidence supports the therapeutic potential of bone marrow (BM)-derived stem/progenitor cells
for end-stage liver disease (ESLD). We recently demonstrated that CD133+ stem/progenitor cell (SPC) reinfusion in pa-
tients with ESLD is feasible and safe and improve, albeit transiently, liver function. However, the mechanism(s) through
which BM-derived SPCs may improve liver function are not fully elucidated. Methods. Here, we characterized the circu-
lating SPCs compartment of patients with ESLD undergoing CD133+ cell therapy. Next, we set up an in vitro model mimicking
SPCs/liver microenvironment interaction by culturing granulocyte colony-stimulating factor (G-CSF)-mobilized CD133+and
LX-2 hepatic stellate cells. Results. We found that patients with ESLD show normal basal levels of circulating hematopoi-
etic and endothelial progenitors with impaired clonogenic ability. After G-CSF treatment, patients with ESLD were capable
to mobilize significant numbers of functional multipotent SPCs, and interestingly, this was associated with increased levels
of selected cytokines potentially facilitating SPC function. Co-culture experiments showed, at the molecular and function-
al levels, the bi-directional cross-talk between CD133+ SPCs and human hepatic stellate cells LX-2. Human hepatic stellate
cells LX-2 showed reduced activation and fibrotic potential. In turn, hepatic stellate cells enhanced the proliferation and
survival of CD133+ SPCs as well as their endothelial and hematopoietic function while promoting an anti-inflammatory
profile. Discussion. We demonstrated that the interaction between CD133+ SPCs from patients with ESLD and hepatic stel-
late cells induces significant functional changes in both cellular types that may be instrumental for the improvement of liver
function in cirrhotic patients undergoing cell therapy.
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Introduction
Cirrhosis is defined as the widespread disruption of
normal liver structure by fibrosis and the formation
of regenerative nodules leading to end-stage liver
disease (ESLD) [1,2]. ESLD is irreversibly associ-
ated with liver failure, and currently, orthotopic liver
transplantation (OLT) is the only curative treatment
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[3].Thus, the development of therapeutic approaches
to prevent or reverse the progression of chronic liver
disease to ESLD is essential.
Chronic liver injury is invariably accompanied by
progressive fibrosis. Indeed, hepatic stellate cells and
myofibroblasts are major fibrogenic cell types that
contribute to extracellular matrix accumulation during
the progression from chronic liver injury/inflammation.
Specifically, hepatic stellate cells, which reside in the
space of Disse outside the liver sinusoids, maintain a
quiescent phenotype and store vitamin A under phys-
iological conditions. However, when liver injury occurs,
they become activated and trans-differentiate into pro-
liferating myofibroblast-like cells, which loose their
vitamin A droplets, express α-smooth muscle actin (α-
SMA) and secrete pro-fibrogenic mediators and extra
cellular matrix proteins [4–6].Therefore, controlling
the activation of the hepatic stellate cells population
is considered a potential therapeutic target.
Growing evidence supports the role of bone marrow
(BM)-derived stem/progenitor cells (SPCs) as an at-
tractive therapeutic approach to ESLD.Animal models
demonstrated that BM-derived SPCs home to damaged
liver tissue and participate to tissue regeneration by
promoting epithelial cell proliferation or decreasing liver
fibrosis [7,8] (reviewed in Behbahan et al.) [9]. In ad-
dition, in recent years, small clinical studies suggested
that the infusion of highly selected BM-derived CD34+
hemopoietic SPCs or whole mononuclear cell prepa-
rations may transiently improve liver function in human
cirrhosis (reviewed inVainshtein et al.,Wang et al., and
Bailey et al. [10–12]. However, the underlying mecha-
nisms, as well as the cellular subset responsible for this
therapeutic effect, remain unclear.
CD133 is a highly conserved antigen that identi-
fies a population with both hematopoietic and
endothelial lineage potential [13–15]. It has been re-
ported that CD133 antigen may be a marker for early
progenitors and long-term repopulating cells with high
engraftment potential.Therefore, purified CD133+ cells
are currently used in clinical transplantation proto-
cols [16–19]. Moreover, the significant increase of
circulating CD133+/ CD14+ cells observed after partial
hepatectomy, but not after other major abdominal
surgery [20], suggests the mobilization of defined
subsets of CD133+ SPCs with potential regenerative
activity after loss of liver tissue. In this view, the com-
bination of portal vein embolization with infusion of
CD133+ BM-derived stem cells substantially in-
creased hepatic regeneration compared with portal vein
embolization alone [21] in patients with malignant liver
lesions. Furthermore, administration of CD133+ SPCs
has already been used therapeutically to promote the
regeneration of post-infarction myocardium [22,23].
On the basis of this background, we previously
demonstrated that CD133+ SPCs spontaneously mo-
bilize in cirrhotic patients undergoing OLT [24].
Subsequently, we investigated whether infusion of pu-
rified, mobilized, CD133+ SPCs may be therapeutically
relevant in ESLD. To this end, we recently com-
pleted a phase I clinical study where increasing
numbers of highly purified CD133+ SPCs, mobi-
lized with granulocyte colony-stimulating factor (G-
CSF), were reinfused through the hepatic artery in 12
patients with ESLD. Our results showed that CD133+
SPCs reinfusion in patients with ESLD is feasible, safe
and may induce the transient improvement of liver
function “to bridge” cirrhotic patients to OLT [25].
Here, for the first time, we characterized the cir-
culating SPCs compartment of cirrhotic patients
undergoing the cell therapy trial. We also investi-
gated the interaction between pluripotent CD133+
SPCs and hepatic stellate cells, which are the major
fibrogenic cell type in the liver microenvironment.
Methods
Patient characteristics
CD133+ SPCs were isolated from leukapheresis (AF)
of 12 G-CSF–treated ESLD patients previously en-
rolled in a phase I clinical trial for CD133+ SPCs
reinfusion through the hepatic artery [25]. Detailed
description of patients characteristics are shown in Sup-
plementary Table SI. As control, CD133+ SPCs were
also isolated from the AF of G-CSF–treated hema-
topoietic stem cell donors (five cases). Peripheral blood
(PB) was obtained from 17 normal age-matched vol-
unteers.The study conformed to the ethical guidelines
of the 1975 Declaration of Helsinki, and written in-
formed consent was obtained by patients and controls.
Ex vivo characterization of the mobilized cells
Phenotypic and functional characterization of the
mobilized cells
Ethylenediamine tetraacetic acid–treated PB samples
were taken from 12 patients with ESLD during the
mobilization phase (1 day before, and then 5 and 14
days after G-CSF treatment). Blood samples from 17
healthy subjects served as controls.
The phenotype of circulating hematopoietic and
endothelial SPCs was evaluated by conventional flow
cytometry analysis as described in Supplementary
Table SII. Endothelial progenitor cells (EPCs) were
defined as CD34+KDR+ events, as previously de-
scribed [26]. Cells (1 × 106) were acquired and
analyzed by FACSDiva software (BD). The analysis
was performed excluding cellular debris in a Side
Scatter (SSC)/Forward Scatter (FSC) dot plot. The
percentage of positive cells was calculated subtract-
ing the value of the appropriate isotype controls.The
absolute number of positive cells per milliliter was cal-
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culated as follows: percentage of positive cells × white
blood cell count (WBC) / 100. Assessment of circu-
lating clonogenic hemopoietic progenitors (CFU-
Cs) was performed with mononuclear cells (MNCs;
2 × 105) in methylcellulose medium, as previously
reported [25]. Colony-forming unit EPCs (CFU-
EPCs) have been evaluated through a commercially
available kit (CFU-Hill liquid medium kit; Stemcell
Technologies, Voden Medical Instruments) [27] fol-
lowing the manufacturer’s instructions. Colonies were
enumerated by an inverted microscope (Axiovert 40,
Zeiss). CFU-EPCs were classically defined as central
clusters of round cells surrounded by spindle-shaped
cells.The PB of ESLD patients (at baseline and after
G-CSF mobilization—day +5) and healthy donors was
centrifuged for 15 min at 1000g within 30 min of col-
lection. The serum was then collected and stored at
−80°C until quantification.The serum levels of study
cytokines/matrix metalloproteinases (MMPs) was mea-
sured by high-sensitivity enzyme-linked immunosorbent
assay (ELISA). MMP-9, hepatocyte growth factor
(HGF), C-X-C motif chemokine 12 (CXCL12) and
vascular endothelial growth factor (VEGF) kits were
from R&D Systems.
CD133+ SPC isolation under Good Manufacturing
Practice conditions
PB MNCs obtained from G-CSF–mobilized standard-
volume AF were centrifuged 10 min at 200g and
resuspended in 95 mL phosphate-buffered saline
(Miltenyi Biotech)/0.01% human serum albumin
(Kedrion) solution. Immunomagnetic selection of
CD133+ SPCs was performed by using the human
CD133+ MicroBead kit (Miltenyi Biotech) and a
CliniMACS device (CliniMACS Plus, Miltenyi
Biotech). After selection, cells were resuspended in
normal saline solution (S.A.L.F.) with 10% of human
serum albumin (Albital 200 g/L, Kedrion; vol:vol) plus
10% dimethyl sulfoxide (Bioniche Pharma; vol:vol)
and cryopreserved in bags using a controlled rate cell
freezer (Nicool Plus, Air Liquide). The preparations
were then stored in the vapor phase of liquid nitro-
gen until reinfusion. Aliquots of each cell preparation
were cryopreserved in vials and employed in co-
culture studies. In all the production steps, aliquots
of the starting material (leukapheresis), of the inter-
mediate and final product were used for quality control
analysis. In the starting materials,WBCs were counted
using the hemocytometer ABX Micros 60 CT-
HORIBA and CD133+ SPCs were counted by flow
cytometry using Stem kit reagents (Beckman Coulter)
and a specific antibody against CD133/2 (Miltenyi
Biotech) using ISHAGE method gating strategy, that
allow to determine the enumeration of viable CD133+
SPCs (expressed as CD45+/7AAD−/CD133+ SPCs).
The CD133+ selected cells were counted using an
automated validated method device based on an in-
tegrated fluorescence microscope (Nucleocounter,
Chemometec) that allows determining the number
of the nucleated cells. The purity of the selected
CD133+ SPCs was assessed by flow cytometry by using
CD133/2 and CD45 antibodies (Beckman Coulter).
The percentage of live cells was also quantitatively
determined by annexin V and propidium iodide (PI)
staining (AnnexinV-FITC Apoptosis Detection kit,
eBioscience). In addition, various hemopoietic/
endothelial SPCs markers (CD34, CD38, CD90,
CD105, CD117, KDR, CD184, c-met,) were de-
tected on isolated CD133+ SPCs by flow cytometry,
as described earlier. In parallel experiments, highly
purified CD133+ SPCs were immunomagnetically iso-
lated from the AF of G-CSF–treated hematopoietic
stem cell donors (five cases), following the manufac-
turer’s instructions and phenotypically and functionally
characterized.
In vitro co-cultures of highly purified CD133+ SPCs
and LX-2 cells
LX-2 cell line
LX-2 human hepatic stellate cell line [28], a gener-
ous gift from Dr. Scott L. Friedman (Mount Sinai
School of Medicine, New York), was maintained in
Dulbecco’s Modified Minimal Essential Medium
(DMEM; Gibco BRL LifeTechnologies) with 2% fetal
bovine serum, 1% L-glutamine and 1% penicillin/
streptomycin and cultured at 37°C and 5% CO2.
Co-culture assays
To determine the interaction of LX-2 and CD133+
SPCs from patients, an indirect co-culture system of
LX-2 and CD133+ SPCs was assembled using transwell
membranes (0.45-µm pore size, Costar; Corning). Ap-
proximately, 10 × 103/cm2 LX-2 were placed in the
lower chamber and 60 × 103/cm2 CD133+ SPCs were
placed on the membrane insert. In co-cultures with
direct cell-cell contact, CD133+ SPCs were seeded onto
LX-2 cells. CD133+ or LX-2 cells cultured alone were
used as controls.To mimic the in vivo microenviron-
ment, where CD133+ SPCs are infused into the liver,
we decided to perform monocultures and co-cultures
in the presence of the medium which is optimal for
LX-2 cells.Therefore, cells were plated and cultured
at 37°C and 5% CO2 in DMEM with 2% fetal bovine
serum, 1% L-glutamine and 1% penicillin/
streptomycin. At 24, 48 and 72 h and, in selected
experiments, 168 h after co-culture assay, cells/
supernatants were characterized as follows.
Cell cycle and apoptosis
Cell viability was assessed with Trypan blue dye ex-
clusion. Cell cycle analysis was performed by flow
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cytometry (FACSCanto BD) after PI (BD Biosci-
ence) staining.The results were analyzed with a ModFit
3.0 software. Apoptosis was evaluated by using a
commercially available kit (Annexin-V-FLUOS Staining
Kit, Roche), following the manufacturer’s instructions.
Flow cytometry analysis of α-SMA expression
Intracellular α-smooth muscle actin (α-SMA) stain-
ing was assessed in LX-2 cells using a fluorescein
isothiocyanate (FITC)-conjugated MoAb anti-human
α-SMA (clone EPR5368; Abcam). Briefly, after fix-
ation with paraformaldehyde (2%) in phosphate-
buffered saline for 30 min at 4°C, cells were
permeabilized with saponin (0.1%) and subsequently
labeled with the FITC-conjugated MoAb anti-α-
SMA for 30 min at 4°C. After washing, a minimum
of 1 × 104 cells were acquired by flow cytometer BD
Accuri C6. Analysis was performed excluding cellu-
lar debris in a SSC/FSC dot plot. Results are expressed
as mean fluorescence intensity values.
Progenitor cell assays
CFU-Cs, together with granulocyte macrophage-
CFU (CFU-GM) and erythroid-burst forming unit
(BFU-E) growth of CD133+ SPCs (5 × 103) was evalu-
ated after culture in methylcellulose medium
(MethoCult H4434; Stem Cell Technologies), as pre-
viously reported [29]. For long-term culture-initiating
cells (LTC-IC) assays, 10 × 103/mL CD133+ SPCs
were plated onto irradiated murine stromal cells (M2-
10B4) with bi-weekly half-medium change. After 5
weeks at 37°C, the cells were then evaluated for their
secondary CFU-C activity in a methylcellulose-
based assay, and the number of LTC-IC was calculated
as previously reported [29].
In vitro angiogenesis
The supernatants of CD133+ SPCs and LX-2 cells,
either alone or cocultured with/without contact,
were harvested and stored (−80°C) until further
characterization. Metalloproteinase (MMP)-9, MMP-
2, tissue inhibitor of metalloproteinase (TIMP)-1,
hepatocyte growth factor (HGF), vascular endothe-
lial growth factor (VEGF), G-CSF, CXC motif
ligand (CXCL)12 and stem cell factor (SCF) con-
centrations were measured in the culture supernatants
by ELISA, according to the manufacturer’s instruc-
tions (R&D Systems).
The angiogenic potential of CD133+ SPCs and
LX-2 cells, either alone or co-cultured with/without
contact, was investigated in the cell culture superna-
tants with the AngioKit assay (TCS Cellworks),
according to the manufacturer’s protocol. AngioKit
assay is supplied as a growing co-culture of human
matrix and endothelial cells (HUVEC) at the earli-
est stages of tubule formation in multi-well plates.
Briefly, equal volumes of cell culture supernatants
were added to the supplied growth medium. Condi-
tioning medium was changed on days 1, 2, 4, 7 and
9. After 12 days of incubation, the cultures were
fixed in cold formalin 2% and subsequently stained
by a tubule staining kit containing anti-CD31 primary
antibody (PECAM-1) conjugated with phosphatase,
relevant secondary antibody and substrate (p-
nitrophenol phosphate) to allow tubule visualization.
The reliability of the Angio-Kit was assessed using
positive (Ctrl-pos) and negative (Ctrl-neg) controls
performed by adding VEGF (2 µg/mL) and suramin
(2 mmol/L), respectively, to the culture media.Tubular
density was monitored using a Zeiss inverted micro-
scope (Axiovert 40) at 2.5 magnification. Micrographs
were collected, and images were analyzed with ImageJ.
CD133+ and LX-2 cells RNA extraction and
microarray data analysis
CD133+ SPCs, isolated from two patients with ESLD
enrolled in the clinical trial, and LX-2 cells were cul-
tured either alone or in contact/no contact co-cultures
for 24 h in the presence of SCF (5 ng/mL). After in-
cubation, cells were harvested and counted.To increase
the purity of CD133+ SPCs after contact co-cultures,
CD133+ SPCs were immunomagnetically isolated, as
described earlier. In a similar way, the fraction of
monocultured CD133+ SPCs was immunomagnetically
selected to exclude differences in gene expression due
to the sorting step/procedure. CD133+ SPCs purity
assessed by flow cytometry was >95% for both co-
cultured and monocultured cells. RNA extraction and
gene expression profiling (GEP) were performed as
previously described [30]. Briefly, total RNA was iso-
lated from 1 × 105 cells for each sample using the
miRNeasy MicroRNA isolation kit (Qiagen) accord-
ing to the manufacturer’s protocol. RNA samples
concentration and purity (assessed as 260/280 nm and
260/230 nm ratios) were evaluated by NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies).
RNA integrity was assessed by using the Agilent 2100
Bioanalyzer (Agilent Technologies). GEP was per-
formed on RNA samples extracted from ESLD
patients-derived CD133+ SPCs (n = 2) and kept/
maintained in mono-culture or in co-culture with or
without contact with LX-2 cells for 24 h. Similarly,
LX-2 cells were profiled at 24 h after mono-culture
or in co-culture with or without contact with ESLD
patients-derived CD133+ SPCs. cDNA synthesis and
biotin-labeled target synthesis were performed using
the GeneAtlas IVT Express Kit according to the pro-
tocol supplied by Affymetrix, starting from 100 ng of
total RNA for each sample.The HG-U219 Array Strips
(Affymetrix) hybridization, staining and scanning were
performed by using the GeneAtlas Platform. Differ-
entially expressed genes (DEGs) were selected on
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robust multiarray average–normalized data through a
supervised analysis by using the Partek GS. 6.6 Soft-
ware Package (http://www.partek.com). DEGs (fold
change [FC] ≥ 1.5 or FC ≤ −1.5) were identified for
the following pair-wise comparisons: CD133+ cells
grown in co-culture with or without contact with LX-2
versus CD133+ cells grown alone, and CD133+ cells
grown in co-culture with contact with LX-2 versus
CD133+ cells grown in co-culture without contact with
LX2. In a similar way, GEP was performed on RNA
samples isolated from LX-2 cells at 24 h after mono-
culture or in co-culture with or without contact with
ESLD patients-derived CD133+ SPCs. DEGs (FC
≥1.5 or FC ≤ −1.5) were identified for the following
pair-wise comparisons: LX-2 cells grown in co-
culture with or without contact with CD133+ cells
versus LX-2 cells grown alone, and LX-2 cells grown
in co-culture with contact with CD133+ cells versus
LX-2 cells grown in co-culture without contact with
CD133+ cells.
Statistical analysis
The results were expressed as mean ± SEM or median
(range).When appropriate, the data were analyzed by
the Wilcoxon test for paired data or Student’s t-test.
Data handling and analysis were performed with SPSS
software version 17.0. A P value <0.05 was consid-
ered statistically significant.
Results
G-CSF mobilized progenitor cells with hemopoietic and
endothelial potential in patients with ESLD enrolled in
the cell therapy trial
To characterize the progenitor cell compartment in
the PB of cirrhotic patients undergoing cell therapy,
upon G-CSF–induced mobilization, we first enumer-
ated and performed functional and phenotypic analysis
of various cellular subsets.The median value of total
WBC count before G-CSF treatment was compara-
ble between ESLD patients and healthy donors (data
not shown) as well as the numbers of circulating
CD133+ and CD34+ cells (Figure 1A,B).
After 5 days of G-CSF treatment, we detected the
mobilization into the PB of CD133+ cells (P < 0.001),
CD34+ cells (P < 0.001; Figure 1A,B) and of se-
lected subsets of the CD34+ population, such as cells
co-expressing the CXCL12 receptor CXCR4 (CD184;
P < 0.001; Figure 1C) or HGF receptor (c-met;
Figure 1. G-CSF mobilizes progenitor cells with hemopoietic potential in patients with ESLD. Phenotypic and functional analysis of PB
cells with ESLD with hemopoietic potential from 13/14 patients before (baseline) and after G-CSF treatment (day 5) and 17 healthy sub-
jects is shown. After G-CSF treatment (day 5), CD133+ (A), CD34+ (B), CD34+184+ (C), CD34+c-met+ (D) cells and CFU-C (E) were
significantly higher than baseline values. Progenitors with epithelial potential (CD34+c-met+; D) were significantly increased at baseline
and further increased after G-CSF treatment. The bold line indicates the median value (*P < 0.05; **P < 0.001).
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P < 0.001; Figure 1D). From the functional point of
view, ESLD patients showed decreased hematopoi-
etic function at baseline as demonstrated by the
significantly lower concentration of PB CFU-C com-
pared with healthy donors (P < 0.001; Figure 1E)
although clonogenic progenitors mobilized at day 5
of G-CSF treatment (P < 0.001; Figure 1E).
Interestingly, the frequency of endothelial CD34+/
VEGFR-2 (KDR)+ progenitors (Figure 2A), as well
as more mature CD34+CD105+ and CD34+CD117+
endothelial cells (Figure 2B,C), significantly in-
creased 5 days after G-CSF treatment (P < 0.05;
P < 0.05 and P < 0.001, respectively). Consistently, a
trend toward increased G-CSF mobilized clonogenic
endothelial CFU-EPC progenitors was observed
despite their low baseline concentration as com-
pared to healthy individuals (P < 0.0001; Figure 2D).
All the SPC subsets detected into the PB upon G-CSF
treatment returned to baseline values by day 14 of
G-CSF administration (data not shown).
Taken together, these results corroborated our pre-
vious results [25,31] showing that ESLD patients are
capable of mobilizing hematopoietic/endothelial SPCs
upon G-CSF treatment or tissue damage.
Next, we investigated the concentration of se-
lected cytokines in the serum of ESLD patients
before and after G-CSF–induced mobilization. At base-
line, HGF/CXCL12 and VEGF/MMP-9 were
significantly increased (P < 0.01) and decreased
(P < 0.05), respectively, compared with normal donors.
However, we found that SPC mobilization was asso-
ciated with increased serum level of molecules such
as MMP-9, HGF and VEGF that facilitate migra-
tion, homing and engraftment of BM-derived SPCs
to the damaged liver [32–35], whereas, as expected,
CXCL12 concentration decreased (Figure 3). Simi-
larly to SPC mobilization, serum level of cytokines
returned to baseline values by day 14 of G-CSF ad-
ministration (data not shown).
CD133+ SPCs inhibit activation of liver stromal cells
which, in turn, promote the hematopoietic and
endothelial phenotype and function of CD133+ SPCs
To shed light on the mechanism of CD133-
dependent transient liver improvement, we performed
in vitro experiments mimicking the interplay between
CD133+ SPCs and a selected cell population of liver
Figure 2. G-CSF mobilizes progenitor cells with endothelial potential in patients with ESLD. Phenotypic and functional analysis of PB
cells with endothelial potential from 14 of 17 patients before and after G-CSF treatment and 10 of 17 healthy subjects is shown. After
G-CSF treatment (day 5), the median numbers of CD34+KDR+(A), CD34+CD105+ (B) and CD34+117+ (C) progenitors were signifi-
cantly higher than baseline values. At variance, the number of CFU-EPC remained almost unchanged, with only three patients showing
increased number after G-CSF treatment. The bold line indicates the median value (*P < 0.05; **P < 0.001; ***P < 0.0001).
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microenviroment. To this aim, the human hepatic
stellate cell line LX-2 and human primary CD133+
SPCs from ESLD patients enrolled in the cell
therapy trial were co-cultured (contact or no-
contact cultures; see Methods).Then, we performed
a functional and molecular characterization of both
cell populations.
Flow cytometry analysis showed that the immuno-
magnetically isolated CD133+ SPCs from ESLD
patients were 90% ± 5 pure and expressed, to a various
degree, the following hemopoietic (CD34+, CD90+,
CD38+, CD184+) and endothelial markers (CD105+,
CD117+, KDR+), as previously described in [25] (Sup-
plementary Table SIII).
Next, we analyzed the phenotype of CD133+ SPCs
from ESLD patients (CD34, CD133, CD90, CD38,
CD117, CD105, KDR, CD184, CD31, CD44 ex-
pression) and of LX-2 cells (CD44, c-met, CD105,
CD90, KDR expression) upon co-culture.We did not
find any significant modification up to 72 h of co-
culture (data not shown).
CD133+/LX-2 cells mutually modify their
molecular phenotype
Next, we investigated the changes in gene expres-
sion induced in ESLD patients-derived CD133+ SPCs
by the co-culture with LX-2 cells by means of the
HG-U219 Array (Affymetrix). Microarray data anal-
ysis allowed us to identify a list of 291 DEGs with FC
≥1.5 or FC ≤ −1.5 in at least one of the pair-wise com-
parisons among CD133+ cells grown in co-culture with
contact with LX-2 cells and CD133+ cells, grown in
co-culture without contact with LX-2 cells and CD133+
cells grown alone (Supplementary Figure S1 and Sup-
plementary Table SIV). The heat map in Figure 4
displays a selection of the DEGs obtained by using a
FC ≥2 as cutoff in at least one of the pairwise com-
parisons listed in Methods. GEP data showed the
downregulation of negative regulators of cell cycle
progression (CDKN1C and CDKN2C) and the
upregulation of FHL2, a positive regulator of cell
proliferation in co-cultured (either in contact or
Figure 3. G-CSF treatment induces increased serum levels of multiple cytokines facilitating migration, homing and engraftment.The base-
line levels of HGF (A) and CXCL12 (C) were significantly higher, and VEGF (B) and MMP-9 (D) levels significantly lower, in patients
with ESLD (n = 12) than in healthy controls (n = 13–16). After G-CSF (day 5), we observed the significant increase of HGF, VEGF and
MMP-9. By contrast, the serum level of CXCL12 significantly decreased after G-CSF treatment.The bold line indicates the median value
(*P < 0.05; **P < 0.001).
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no-contact) CD133+ SPCs versus CD133+ SPCs cul-
tured alone. In addition, only the co-culture with LX-2
cells induced the upregulation of apoptosis inhibi-
tors (PIM1, PIM2, BCL6) in CD133+ SPCs
(Figure 4).Taken together, these results indicate that
the interaction with hepatic stellate cells LX2 induces
a proliferative molecular phenotype of CD133+ SPCs.
Noteworthy, the co-culture in contact with LX-2 cells
Figure 4. The co-culture with LX-2 cells affects the molecular phenotype of CD133+ SPCs from ESLD patients. Hierarchical clustering
and heat map analysis for the transcripts differentially expressed (i.e., up-regulated, FC ≥2 or down-regulated, FC ≤ −2) in CD133+ SPCs
from ESLD patients (n = 2) co-cultured (with or without contact) with LX-2 cells as compared with CD133+ SPCs cultured alone. The
signal-based coloring legend is shown at the bottom of the panel. For each transcript, red bars indicate relatively high signal intensity,
while green bars represent lower intensity and black intermediate. The clustering of the samples is indicated by the dendrogram on top.
Microarray analysis was performed in duplicate (indicated as ESLD patient 1 and ESLD patient 2).
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induced the up-regulation of several genes promot-
ing angiogenesis (CXCL3, ID1,VEGFC, SERPINE1,
SELP, SCL2A14, VEGFA, CYP1B1) and the
downregulation of genes encoding for inhibitors of an-
giogenesis (SPON2, vWF) and promoters of
inflammation (LTC4S, SPON2) in CD133+ SPCs
(Figure 4). Thus, the interaction with LX-2 liver
stromal cells induces a pro-angiogenic and anti-
inflammatory phenotype in CD133+ SPCs, the former
requiring cell–cell contact.
We then analyzed the gene expression changes
induced in LX-2 cells by the co-culture with ESLD
patients-derived CD133+ SPCs by Affymetrix HG-
U219 Array. Microarray data analysis highlighted a list
of 664 DEGs with FC ≥1.5 or FC ≤ −1.5 in at least
one of the pair-wise comparisons (see Methods) among
LX-2 cells grown in co-culture with or without contact
with CD133+ cells and LX-2 cells grown alone
(Supplementary Figure S2 and Supplementary
Table SV). Of note, microarrays analysis highlighted the
down-regulation of genes promoting hepatic stellate cells
activation and fibrosis (CEBPB, FOXF1, TLR4,
SMAD1, SMAD5, COL1A1, COL3A1, COL6A3,
COL12A1, MMP1, MMP2, TIMP1) in co-cultured
LX-2 cells in comparison with LX-2 cells grown alone,
whereas SMAD6 (a negative regulator of the pro-
fibrotic TGF-β signaling pathway) and NFKBIB (an
inhibitor of NFkB-mediated proinflammatory signal-
ing) were up-regulated upon co-culture. Interestingly,
microarray data also unveiled the down-regulation of
genes coding for proinflammatory cytokines (interleukin-
1B and -8) and profibrotic mediators (fibroblast growth
factor-2 and -5) in co-cultured LX-2 cells compared
with LX-2 cells alone (Figure 5).
CD133+ SPCs inhibit activation of LX-2 cells
During liver fibrosis hepatic stellate cells express
fibrosis-related genes such as α-SMA, which pro-
motes contractile force and extra-cellular matrix
stiffness [36].Thus, to support functionally GEP data
relative to the down-regulation of genes promoting
hepatic stellate cells activation and fibrosis in co-
cultured LX-2 cells, we tested by flow cytometry the
expression of α-SMA. Consistently with GEP data,
at the functional level, the percentage of the cells ex-
pressing α-SMA was significantly decreased in LX-2
cells after 48 h of co-culture with CD133+ SPCs
(Figure 6; contact co-cultured cells versus LX-2 cells
alone P < 0.05; no contact co-cultured cells vs LX-2
cells P < 0.05).
LX-2 cells promote viability and proliferation
of CD133+ SPCs
To investigate whether LX-2 cells may influence the
function of CD133+ SPCs from ESLD patients, we
studied their viability, apoptosis and hematopoietic
function upon co-culture. As shown in Figure 7A
and 7B, CD133+ SPCs from patients with ESLD,
co-cultured in contact or without contact, with
LX-2 cells showed, at different time points, the
significant increase of survival coupled with the
reduction of apoptosis as compared with CD133+
SPCs cultured alone. These data are consistent
with microarray data showing the modulation of
proliferation/survival genes in CD133+ SPCs co-
cultured with LX-2 cells. Of note, the same pattern
(viability/apoptosis) was observed when CD133+ SPCs
from healthy donors were co-cultured with LX-2
cells up to 72 hours (Supplementary Figure S3A,B).
In contrast, the viability of LX-2 cells was unaffected
Figure 5. The gene expression changes unveil that patient-
derived CD133+ SPCs could restrain LX-2 cell activation.
Hierarchical clustering and heat map analysis for the transcripts
coding for proteins involved in hepatic stellate cells activation and
differentially expressed (i.e., up-regulated, FC ≥1.5 or down-
regulated, FC ≤ −1.5) in LX-2 cells co-cultured (with or without
contact) with ESLD patient-derived CD133+ SPCs compared with
LX-2 cells cultured alone.The signal-based coloring legend is shown
at the bottom of the panel. For each transcript, red bars indicate
relatively high signal intensity, whereas green bars represent lower
intensity and black intermediate. The clustering of the samples is
indicated by the dendrogram on top.
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by the co-culture with CD133+ SPCs from ESLD
patients (Supplementary Figure S4).
Cell cycle analysis showed that CD133+ SPCs from
ESLD patients and co-cultured in direct contact with
LX-2 cells for 48 h increased significantly (P < 0.05)
the percentage of cells in the G2/M phase (12 ± 6.2%)
compared with CD133+ SPCs alone (6.1 ± 4.4%) and
decreased the percentage of cells in the G0/G1 phase
(Figure 8). Similarly, normal CD133+ SPCs showed
the same kinetic pattern when cocultured with LX-2
cells (data not shown). On the contrary, cell cycle dis-
tribution in LX-2 cells was unaffected by the co-
culture with CD133+ SPCs (Supplementary
Figure S5).Thus, functional assays demonstrated that
the interaction with LX-2 liver stromal cells led to en-
hanced cycling and reduced apoptosis in CD133+
SPCs.
Moreover, we found that the number of CFU-C
from contact co-cultured CD133+ SPCs was signifi-
cantly increased (P < 0.05), compared with CD133+
SPCs alone, after 72 and 168 h of co-culture
(Figure 7C). Interestingly, as shown in Supplementary
Figure S6, also the size of either CFU-GM or BFU-E
colonies increased, suggesting the higher cycling ca-
pacity of lineage-specific cells. In addition, we found
that CD133+ SPCs co-cultured with LX-2 cells, either
with or without contact, showed the significant in-
crease of primitive hematopoietic progenitors as
determined by LTC-IC assay (P < 0.05 and P < 0.01,
respectively; Figure 7D). Parallel experiments dem-
onstrated that the clonogenic ability of co-cultured
CD133+ SPCs from healthy donors was superimposable
to that of ESLD patients (Supplementary Figure S3C).
LX-2 cells enhance angiogenetic potential of
CD133+ SPCs
We next evaluated whether the bi-directional cross-
talk between CD133+ SPCs and LX-2 cells is regulated
by cytokines/growth factors release in the superna-
Figure 6. CD133+ SPCs from ESLD patients inhibit activation of LX-2 cells. Flow cytometry analysis of α-SMA expression in LX-2 cells
after in vitro co-cultures, either in contact or without contact, with CD133+ SPCs from ESLD patients (n = 13 is shown. Representative
dot plots showing α-SMA expression of isotype control (A), LX-2 cells alone (B) and LX-2 cells after in vitro co-cultures with CD133+
SPCs in contact (C) and without contact (D). The gates show the percentage of positive cells using the isotype control as reference. (E)
Bar graph: the percentage of α-SMA positive cells was significantly decreased in LX-2 cells after 48 h of in vitro co-culture with CD133+
SPCs (light gray and white columns) compared with LX-2 cells cultured alone (black column). Results are expressed as mean ± SEM
(*P < 0.05).
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tants of co-cultured cells. As shown in Figure 9A,
LX-2 cells produced a time-dependent increasing
amount of VEGF independently from the presence
of CD133+ SPCs. Interestingly, HGF, SCF, G-CSF
and CXCL12 proteins were absent in the supernatants
at any condition/time tested as well as the MMP9,
MMP2 and TIMP1 (data not shown).
On the basis of the VEGF production results, we
functionally tested the angiogenic potential of the su-
pernatants of mono/co-cultured cells. We found that
supernatants of co-cultured cells stimulated tube for-
mation when added to HUVEC cell line. Quantitative
analysis of the total area (mm2) of tubes showed that
both the supernatant of contact and no contact co-
cultures as well as that of LX-2 alone increased the
total tubules area indicating that LX-2-produced
soluble factors are able to induce angiogenic activity
(Figure 9B,C). Interestingly, a slight, but significant,
increase in the total tube area was observed when
CD133+ SPCs were cultured in contact with LX-2 liver
cells (Figure 9C).
Discussion
We have recently completed a phase I clinical trial in
which we demonstrated the safety and the feasibility
of the intrahepatic reinfusion of G-CSF–mobilized,
highly purified CD133+ SPCs in cirrhotic patients [25].
Similarly to other studies, we were able to show the
significant, although transient, improvement of liver
function after CD133+ SPC injection (as reviewed in
Houlihan and Newsome, Nikeghbalian et al., and
Margini et al.) [37–40]. Thus, we suggest that stem
cell therapy may be an attractive “bridge to trans-
plant” approach for ESLD patients.
However, the mechanism(s) through which BM-
derived SPCs improve liver function are not fully
elucidated. Some insights from animal models support
the view that SPCs may exert their activity through
the release of cytokines acting through a paracrine
mechanism [9,41,42] rather than by trans-
differentiation [43,44] or cell fusion [45,46]. In this
view, clinical trials did not provide any further data
Figure 7. LX-2 cells promote viability and stimulate the short- and long-term clonogenic ability of patients-derived CD133+ SPCs. CD133+
SPCs from patients with ESLD (n = 10) were in vitro co-cultured with LX-2 cells, either in contact or without contact, at different time
points and, along with survival/apoptosis, short- (CFU-C) and long-term (LTC-IC) clonogenic activity were monitored. (A and B) The
CD133+ SPCs from patients with ESLD co-cultured in contact with LX-2 cells showed a significant increase of survival with concomitant
reduction of apoptosis as compared with the respective mono-cultured counterparts. Results are expressed as mean fold change compared
with CD133+ SPCs alone ± SEM. (C) The mean number of CFU-C from contact co-cultured CD133+ SPCs was significantly increased
compared with the mono-cultured counterparts after 72 and 168 h of incubation. Results are expressed as mean ± SEM. (D) After 72 h
of in vitro co-cultures, either in contact or without contact, CD133+ SPCs from ESLD patients showed a significant increase in the long-
term clonogenic capacity (LTC-IC number) compared with the mono-cultured counterparts. Results are expressed as mean ± SEM (*P < 0.05;
**P < 0.001; ***P < 0.0001).
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owing to the variability in cell source (e.g., BM or mo-
bilized SPCs), route of administration, use of selected/
unselected stem/progenitor cells and lack of liver
biopsies before and after cell therapy. In the present
study, we characterized CD133+ SPCs of ESLD pa-
tients previously enrolled in our clinical study, with
specific reference to the interaction between CD133+
SPCs and the human hepatic stellate cells LX-2.
Here, we demonstrated that ESLD patients show
basal levels of circulating hematopoietic and endo-
thelial progenitors comparable with those detected in
healthy donors. Consistent with a previous study, pa-
tients with chronic cirrhosis had similar numbers of
circulating CD133+/CD34+ cells compared with healthy
people [47].This finding indicates that severe chronic
liver injury, by itself, probably does not stimulate mo-
bilization of BM-derived cells into PB. However, both
the hematopoietic and the endothelial potential, evalu-
ated as CFU-C and CFU-EPC growth, respectively,
were impaired in cirrhotic patients.
Conversely, after G-CSF treatment, patients with
chronic liver diseases were able to mobilize signifi-
cant numbers of functional hemopoietic/endothelial
stem/progenitor cells as previously reported by our
group and others [31,48–51], although to a lesser
extent than healthy control subjects as demon-
strated by the higher dose of G-CSF required to
mobilize relatively low numbers of SPCs in compar-
ison with healthy BM stem cells donors (15 versus
10 µg/kg/day). This is probably due to sequestration
of circulating BM-derived stem cells in the spleen and/
or impaired BM function secondary to cirrhosis and/
or infection-related cirrhosis.
We have demonstrated that SPC mobilization was
associated with increased serum levels of molecules
such asVEGF and MMP-9, which are involved in the
process of cell migration, matrix degradation and an-
giogenesis. In addition, in line with the increased
number of circulating CD34+CXCR4+ progenitors, the
serum levels of SDF-1 were significantly reduced after
G-CSF administration, likely due to CXCR4 binding.
Moreover, the increased number of circulating pro-
genitors co-expressing CXCR4 suggests increased
trafficking and, perhaps, homing and engraftment to
the damaged liver as shown in animal models [33].
Thus, it may well be that BM-derived SPCs with
hematopoietic/endothelial potential contribute to im-
proving tissue function in case of acute or chronic liver
injury.
As previously reported [25], performing liver bi-
opsies in ESLD patients enrolled in our trial was
considered not ethically justified; indeed, the histo-
pathology examination of the explanted liver in five
patients undergoing OLT did not reveal the pres-
ence of residual CD133+ SPCs, and the fibrotic and
angiogenetic pattern was not significantly different, at
first glance, from control samples (i.e., OLT recipi-
ents who did not receive cell therapy). Whether this
finding was due to the timing of this retrospective anal-
ysis (performed at a median time of 109 days after
cell therapy) [25], which may have missed some early
biological modifications induced by the reinfused
CD133+ SPCs, remains a matter of discussion.
We therefore investigated, in vitro, the putative
mechanisms of interaction between CD133+ SPCs and
the human hepatic stellate cells LX2. In this regard,
molecular and functional assays unveiled the inter-
play between the two cell populations.
The proliferation and activation of hepatic stel-
late cells play an essential role during the process of
liver fibrogenesis. Therefore, reversal or suppression
of hepatic stellate cells activation is considered as a
main target for therapeutic approaches addressing
hepatic fibrosis. In this study, we used the immortal-
ized LX-2 cell line, which has been shown to retain
the features of activated hepatic stellate cells, includ-
ing α-SMA expression [28] and therefore are suitable
to give an indication of the responses of hepatic stel-
late cells in vivo [52]. Of note, despite the fact that
CD133/LX2 co-culture experiments do not dupli-
cate the complexity of the liver microenvironment in
vivo and other cellular elements should probably be
taken into account as playing a role in the hepatic mi-
croenvironment, LX-2 cells are nonetheless considered
a valuable tool for analysis of human hepatic fibro-
sis.We performed LX-2 co-culture experiments to gain
Figure 8. LX-2 cells promote cell proliferation in CD133+ SPCs
from patients with ESLD. CD133+ SPCs from patients with ESLD
(n = 10) were in vitro co-cultured for 48 h with LX-2 cells, either
in contact or without contact, and their distribution in the differ-
ent phases of cell cycle was assessed by PI staining. Cells cultured
in direct contact presented a slight, but significant, increase in the
percentage of cells in phase G2-M, whereas the percentage of cells
in G0-G1 was decreased. Data are represented as mean ± SEM
(*P < 0.05).
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insight into the potential effects of CD133+ on key
hepatic fibrogenic cells.
Indeed, the profiling of the gene expression changes
associated with the co-culture of CD133+ and LX-2
cells provided important insights into the cross-talk
between these populations by highlighting the up-
regulation of antiapoptotic and pro-angiogenic genes
and the down-regulation of inhibitors of cell cycle pro-
gression and angiogenesis in CD133+ SPCs, together
with the down-regulation of genes promoting hepatic
stellate cell activation and fibrosis in LX-2 cells. In
line with these data, functional assays showed that
CD133+ SPCs inhibit LX-2 cells activation by de-
creasing α-SMA expression. In turn, LX-2 cells
promoted CD133+ SPCs proliferation/survival and he-
matopoietic function, suggesting supportive effects of
human hepatic stellate cells on hemopoiesis in ESLD
patients.These data are consistent with a recently pub-
lished paper demonstrating that the microevironmental
cues of diseased liver are able to influence the cell cycle
and the hemopoietic programming fate of liver resi-
dent CD34+ cells [53]. In addition, LX-2 cells, through
VEGF production, stimulated, in vitro, CD133+ cell-
driven angiogenesis. This finding may be important
in ESLD patients, in whom endothelial cell dysfunc-
tion is a central mechanism in the pathogenesis of
portal hypertension. In addition, although VEGF is
unequivocally a pro-fibrogenic mediator and has a well
established role in endothelial cells survival/proliferation,
it may have also a role in fibrosis resolution by po-
Figure 9. LX-2 cells enhance the angiogenetic potential of CD133+ SPCs from ESLD patients. (A) ELISA analysis of VEGF levels in the
supernatants of co-cultures of CD133+ SPCs from ESLD patients (n = 10) and LX-2 cells after 24, 48, 72 and 168 h of incubation. LX-2
cells synthesize a time-dependent increasing amount of VEGF; however, this production was not significantly modified by the presence of
CD133+ SPCs. Results are expressed as mean ± SEM. (B and C) Supernatants (n = 10) of mono-cultured CD133+ SPCs from ESLD
patients/LX-2 cells or co-cultured cells (in contact and no contact) after 1 week of incubation have been added to HUVEC cell line. Su-
pernatants of co-cultured cells stimulate tubules formation (B,d) and increased the total tubules area (C) compared with mono-cultured
CD133+ SPCs. However, a significant difference was observed only with the contact co-cultures supernatants (C). Results are expressed
as mean ± SEM (*P < 0.05).
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tentially increasing the recruitment of “resolution”
macrophages, which have an important role in fibrosis
reversal [54]. Moreover,VEGF may accelerate fibrolysis
via CXCL9/MMP13 axis [55].
Overall, the present study demonstrates that there
is bi-directional cross-talk between CD133+ SPCs from
patients with ESLD and the human hepatic stellate
LX-2 cells. This interaction promotes positive func-
tional modifications in both cellular types. We can
therefore hypothesize a scenario in which, after cell
therapy, the activated hepatic stellate cells of the liver
microenvironment could stimulate the hemopoietic and
endothelial potential of the CD133+ SPCs, which, in
turn, might contribute to switch off the activation of
the hepatic stellate cells.These findings open new per-
spectives for cell therapy in patients with advanced
chronic liver diseases.
Conclusions
We demonstrated that mobilized CD133+ SPCs from
patients with ESLD may be a good candidate for cell
therapy in cirrhotic patients given their potential to
participate/trigger reparative processes. In turn, hepatic
stellate cells, key players in the liver microenviron-
ment, enhance the endothelial and hemopoietic
potential of the mobilized cells from ESLD patients.
This finding highlights the potential reparative role of
CD133+ SPCs for severely diseased liver.
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